Oxford Pharmascience Group Plc

Activities: Drug Delivery Research & Development Pharmaceutical Patient Experience

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards...
  3. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  4. Resolving capping issues in tablet manufacturing Natoli explores the various causes of capping and the methods to prevent it
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

A matter of taste

Unpalatability of pharmaceutical products, particularly paediatric medicines, can adversely affect patient compliance. Ideally a taste-masking technology should not add to manufacturing time or cost and should not affect bioavailability of the active ingredient. OXP zero is a novel salt system that allows anionic drugs to be administered orally without bad taste or irritation. The API is surrounded in a protective, layered structure that is insoluble in the mouth but it readily releases the API in the stomach.
Ingredients

Oxford Pharmascience to develop OxpZero taste-masking product

Will initially focus its efforts on NSAIDs
Drug Delivery

Oxford firm licenses colonic drug delivery technology

The license is from The School of Pharmacy, University of London
Subscribe now